Patents by Inventor Akin Akinc

Akin Akinc has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240344066
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the beta-catenin (CTNNB1) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a CTNNB1 gene and to methods of preventing and treating a CTNNB1-associated disorder, e.g., cancer, e.g., hepatocellular carcinoma.
    Type: Application
    Filed: January 5, 2024
    Publication date: October 17, 2024
    Inventors: Akin Akinc, Jeffrey Zuber
  • Publication number: 20240285768
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Application
    Filed: March 4, 2024
    Publication date: August 29, 2024
    Inventors: Martin MAIER, Muthusamy JAYARAMAN, Akin AKINC, Shigeo MATSUDA, Pachamuthu KANDASAMY, Kallanthottathil G. RAJEEV, Muthiah MANOHARAN, Jayaprakash K. NAIR, Thomas A. BAILLIE
  • Publication number: 20240285767
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Application
    Filed: February 28, 2024
    Publication date: August 29, 2024
    Inventors: Martin MAIER, Muthusamy JAYARAMAN, Akin AKINC, Shigeo MATSUDA, Pachamuthu KANDASAMY, Kallanthottathil G. RAJEEV, Muthiah MANOHARAN, Jayaprakash K. NAIR, Thomas A. BAILLIE
  • Publication number: 20240269289
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Application
    Filed: February 28, 2024
    Publication date: August 15, 2024
    Inventors: Martin MAIER, Muthusamy JAYARAMAN, Akin AKINC, Shigeo MATSUDA, Pachamuthu KANDASAMY, Kallanthottathil G. RAJEEV, Muthiah MANOHARAN, Jayaprakash K. NAIR, Thomas A. BAILLIE
  • Publication number: 20240254491
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the beta-catenin (CTNNB1) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a CTNNB1 gene and to methods of preventing and treating a CTNNB1-associated disorder, e.g., cancer, e.g., hepatocellular carcinoma.
    Type: Application
    Filed: February 20, 2024
    Publication date: August 1, 2024
    Inventors: Akin Akinc, Jeffrey Zuber
  • Publication number: 20240245778
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Application
    Filed: March 4, 2024
    Publication date: July 25, 2024
    Inventors: Martin MAIER, Muthusamy JAYARAMAN, Akin AKINC, Shigeo MATSUDA, Pachamuthu KANDASAMY, Kallanthottathil G. RAJEEV, Muthiah MANOHARAN, Jayaprakash K. NAIR, Thomas A. BAILLIE
  • Publication number: 20240093199
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the PCSK9 gene (PCSK9 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the PCSK9 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier and method for treating diseases caused by PCSK9 gene expression.
    Type: Application
    Filed: March 3, 2023
    Publication date: March 21, 2024
    Inventors: Pamela Tan, Birgit Bramlage, Maria Frank-Kamenetsky, Kevin Fitzgerald, Akin Akinc, Victor E. Kotelianski
  • Publication number: 20240076664
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F12) gene, or the Kininogen 1 (KNG1) gene, and methods of using such RNAi agents to inhibit expression of a KLKB1 gene, an F12 gene, and/or a KNG1 gene, and methods of treating subjects having an hereditary angioedema (HAE) and/or a contact activation pathway-associated disorder.
    Type: Application
    Filed: July 5, 2023
    Publication date: March 7, 2024
    Inventors: Akin Akinc, Gregory Hinkle, Martin A. Maier, James Butler, Jingxuan Liu
  • Publication number: 20230365965
    Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia.
    Type: Application
    Filed: January 17, 2023
    Publication date: November 16, 2023
    Applicant: Genzyme Corporation
    Inventors: Akin Akinc, Alfica Sehgal, Ivanka Toudjarska, Donald Foster, Stuart Milstein, Brian Bettencourt, Martin A. Maier, Klaus Charisse, Satyanarayana Kuchimanchi, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • Publication number: 20230287424
    Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents for administration by inhalation preferably targeting genes expressed in the respiratory system, as well as methods of inhibiting expression of a target gene after administration by inhalation, preferably a gene expressed in the respiratory system.
    Type: Application
    Filed: December 8, 2022
    Publication date: September 14, 2023
    Inventors: Christopher Brown, Donald Foster, Arlin Rogers, Vasant R. Jadhav, Akin Akinc, Amy R. Simon
  • Publication number: 20230256098
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Application
    Filed: April 20, 2023
    Publication date: August 17, 2023
    Inventors: Martin MAIER, Muthusamy JAYARAMAN, Akin AKINC, Shigeo MATSUDA, Pachamuthu KANDASAMY, Kallanthottathil G. RAJEEV, Muthiah MANOHARAN
  • Publication number: 20230193284
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the transmembrane serine protein 2 (TMPRSS2) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a TMPRSS2 gene and to methods of treating or preventing a TMPRSS2-associated disease, e.g., COVID-19, in a subject.
    Type: Application
    Filed: September 30, 2022
    Publication date: June 22, 2023
    Inventors: Akin Akinc, James D. McIninch, Yesseinia Anglero-Rodriguez, Mark K. Schlegel
  • Patent number: 11679158
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: June 20, 2023
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • Publication number: 20230174459
    Abstract: Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described.
    Type: Application
    Filed: July 13, 2022
    Publication date: June 8, 2023
    Applicant: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Akin Akinc, Jayaprakash K. Nair, Muthusamy Jayaraman, Martin Maier
  • Publication number: 20230158058
    Abstract: The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to treat a bleeding event in a subject having a hemophilia (e.g., with or without inhibitors).
    Type: Application
    Filed: August 1, 2022
    Publication date: May 25, 2023
    Applicant: Genzyme Corporation
    Inventor: Akin Akinc
  • Publication number: 20230133147
    Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the angiotensin converting enzyme 2 (ACE2) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an ACE2 gene and to methods of treating or preventing an ACE2-associated disease, e.g., COVID-19, in a subject.
    Type: Application
    Filed: September 30, 2022
    Publication date: May 4, 2023
    Inventors: Akin Akinc, James D. McIninch, Yesseinia Anglero-Rodriguez, Mark K. Schlegel
  • Patent number: 11633479
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: April 25, 2023
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • Patent number: 11633480
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: April 25, 2023
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • Patent number: 11612657
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: March 28, 2023
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • Patent number: 11590229
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: February 28, 2023
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan